The eTOX project aimed to develop a drug safety database from the pharmaceutical industry legacy toxicology reports and public toxicology data, as well as innovative in silico strategies and novel software tools to better predict the toxicological profiles of small molecules in early stages of the drug development pipeline.
This 7 year project, funded by the Innovative Medicines Initiative Joint Undertaking, a unique partnership between the European Community and the European Federation of Pharmaceutical Industries and Associations (EFPIA), was a collaboration of 13 pharmaceutical companies and 17 academics/SMEs.
The project has now come to an end, but the legacy continues with eTOXsys. Find out more about eTOXsys here.
The following points provide a greater insight into the eTOX project and Lhasa Limited's role within it:
- The project's full title was "Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities.
- The aim was to develop new methodological strategies and tools to better predict the toxicological profiles of new drug candidates.
- The consortium included EFPIA members, academics and SMEs. Details on consortium members are available on the eTOX website.
- Lhasa Limited acted as the honest broker:
- Hosting the central database containing shared legacy data from non-clinical safety studies for small molecules donated by the participating pharmaceutical companies.
- Responsible for data security and data curation including linking to ontologies being developed within the project.
- The eTOX roadmap, complete with work packages has been included below.
Take a look at our eTOX library for a variety of related references.
- Improved efficiency -
- Toxicity related adverse events continue to be a leading cause of new drug candidates erosion at all stages. Analysis of the reasons for previous failures and exploitation of them, could help lead to a more efficient drug development process.
- Time and cost savings -
- The database contains data from several thousand repeat dose toxicity studies making it ideal for read-across during early drug development.
- Mining of the data could allow development of more reliable in silico models, linking structural features and/or in vitro data with toxicological readouts.
- Access to all this information early in development allows for informed decision making, providing opportunity to save costs on lengthy experiments for candidates that are considered inappropriate.
Lhasa Limited - an honest broker and trusted holder of data
Lhasa is a not-for-profit organisation and we believe that shared knowledge can lead to shared progress. Recognised as the original honest broker, Lhasa Limited has repeatedly been trusted with proprietary data and this can be seen with our involvement in other collaborative data sharing projects. These include:
- Aromatic Amines Aims to improve the understanding and predictability of the Ames test outcome for primary aromatic amines.
- Elemental Impurities Shares analytical data on the levels of trace metals within batches of excipients and aims to increase understanding of the level of risk posed by elemental impurities.
- iPiE Aims to develop frameworks to support the environmental testing of new pharmaceuticals and to help prioritise testing of legacy APIs.
- Vitic Excipients Shares data on the effects of pharmaceutical excipients and aims to refine experiments and contribute towards a reduction of animal numbers required for testing.
- Vitic Intermediates Shares data resulting from Ames mutagenicity assays performed on common Intermediates and compounds containing functional groups of interest.
It is not possible for additional partners to join the consortium at this stage, however access to the predictive system and databases developed within the eTOX consortium, will be made available to the scientific community on completion of the project through a business solution.
Check out the eTOX website for further details on this project.
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115002 (eTOX), resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contributions.